Pulse Biosciences Inc ( (PLSE) ) has released its Q4 earnings. Here is a breakdown of the information Pulse Biosciences Inc presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Pulse Biosciences Inc., a bioelectric medicine company, specializes in nanosecond Pulsed Field Ablation technology, aiming to revolutionize soft tissue ablation and cardiac treatments. The company recently reported its financial results for the fourth quarter and full year of 2024, highlighting significant advancements in its clinical trials and strategic appointments. Key highlights include positive preliminary results from its thyroid nodule treatment study and advancements in its atrial fibrillation treatment programs. Financially, the company reported increased expenses due to expanded operations and stock-based compensation, resulting in a higher net loss compared to the previous year. Looking forward, Pulse Biosciences plans to initiate several clinical trials in 2025, focusing on the commercialization of its soft tissue ablation technology and further development of its cardiac treatment systems.